Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This review explores prostate cancer risk factors, screening, treatment, and potential roles of selenium and 5-alpha reductase inhibitors in risk reduction but presents no new clinical data.

Finasteride reduces prostate size and symptoms with few side effects.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This article discusses the evolving field of hair transplantation surgery and reports no new experimental results, highlighting ongoing developments aimed at improving procedural success and doctor efficacy.

This review discusses the impact of various treatments for prostate cancer, noting that while 5α-reductase inhibitors reduce risk, they may not decrease and could even increase high-risk cancers; the authors highlight that recent data suggest longer screening can reduce prostate cancer mortality more effectively.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.

This clinical trial in Poland found that using finasteride, alone or with an alpha-blocker, reduced prostate adenoma size by 40% and improved micturition in patients with benign prostatic hyperplasia.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study discusses the role of 5α-reductase inhibitors in managing lower urinary tract symptoms caused by benign prostatic hyperplasia and suggests their potential use in other conditions like prostate cancer chemoprevention and androgenetic alopecia treatment, emphasizing appropriate dosing to reduce surgical complications.

Dr. Yarborough denied endorsing Derma Genesis and was mistakenly represented due to his office manager's error; also, over 30% of tested skin products were contaminated with bacteria.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This article reviews the use of 5α-reductase inhibitors for treating benign prostatic hyperplasia, suggesting potential benefits beyond symptom relief, but it reports no new clinical results.

This review reports that treatments for urological cancers, such as chemotherapy and immunotherapy, often result in significant dermatological side effects that negatively affect patients' quality of life and treatment adherence, highlighting a need for better management strategies and further research.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This review examines natural bioactive compounds for their potential to alleviate androgenetic alopecia, emphasizing compounds like ginseng and curcumin, but reports no new experimental results.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

In this case study, a male miniature dachshund with alopecia was diagnosed with estrogen-secreting Sertoli cell tumors and seminoma, with the alopecia resolving post-surgical removal of the tumor.